Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
NET REVENUE
Clinical testing revenue	$ 56,316	$ 24,055	$ 110,936	$ 46,894
BioPharma & research revenue	6,813	315	11,896	502
Total Revenue, net	63,129	24,370	122,832	47,396
COST OF REVENUE	34,524	13,557	67,055	27,040
GROSS MARGIN	28,605	10,813	55,777	20,356
Operating expenses:
General and administrative	18,779	7,075	36,785	13,598
Research and development	1,306	803	2,752	1,471
Sales and marketing	6,327	2,907	12,127	5,821
Total Operating Expenses	26,412	10,785	51,664	20,890
INCOME (LOSS) FROM OPERATIONS	2,193	28	4,113	(534)
Interest expense, net	1,448	189	3,040	384
Income (loss) before taxes	745	(161)	1,073	(918)
Income tax expense	332	15	505	19
NET INCOME (LOSS)	413	(176)	568	(937)
Deemed dividends on preferred stock	1,840		3,680
Amortization of preferred stock beneficial conversion feature	3,727		7,453
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	$ (5,154)	$ (176)	$ (10,565)	$ (937)
NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS
Basic	$ (0.07)	$ 0.00	$ (0.14)	$ (0.02)
Diluted	$ (0.07)	$ 0.00	$ (0.14)	$ (0.02)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic	77,448	60,425	76,758	60,352
Diluted	77,448	60,425	76,758	60,352